Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Human thrombin is a platelet activating factor used to treat minor bleeding. Human thrombin is a sterile solution, pH 6.8-7.2, containing highly purified human thrombin for the activation of clotting.
- Mechanism
- Curator reviewed
Human thrombin (coagulation factor IIa) is a highly specific protease that transforms plasma fibrinogen into fibrin which, in the presence of clotting factor XIII in the patient's plasma, is cross-linked to form a stable clot. When applied to a surgical wound where bleeding is present, thrombin activates fibrinogen in the patient's plasma to form fibrin, which results in clot formation and hemostasis. The fibrin clot is stabilized by cross-linking occurring as a result of activation of the patient's endogenous factor XIII, which requires the presence of calcium.
Human thrombin does not require any intermediate physiological agent because it naturally clots the fibrinogen of the blood directly. Any failure to clot blood occurs in the rare case where the primary clotting defect is the absence of fibrinogen itself. The speed with which human thrombin clots blood is dependent upon the concentration of both the human thrombin used and fibrinogen present.
- Primary indication
- Human thrombin is indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules are accessible and control of bleeding by standard surgical techniques (such as suture, ligature, or...Curator reviewed · 7 structured indications
- First approval
- Canada, 2006 · United States, 1998 · European Union, 2016
- Also known as
- Thrombin (human) · Thrombin human · Thrombin Human Plasma-derived
- Brand names
- Artiss
- Evarrest
- Evicel
- Evithrom
- Tachosil
- Tisseel
- Veraseal
- Vistaseal
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with Human thrombin, and which of those have an active Phase 3 trial?